Rituximab therapy in malignant lymphoma
B Coiffier - Oncogene, 2007 - nature.com
Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell
lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL) …
lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL) …
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
RS Cvetković, CM Perry - Drugs, 2006 - Springer
Summary Abstract Rituximab (MabThera®, Rituxan®) is an anti-CD20 monoclonal antibody
that induces lysis and apoptosis of normal and malignant human B cells, and sensitises …
that induces lysis and apoptosis of normal and malignant human B cells, and sensitises …
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness
J Schwaller, P Schneider, P Mhawech-Fauceglia… - Blood, 2007 - ashpublications.org
Abstract A PRoliferation-Inducing TNF Ligand (APRIL) costimulates B-cell activation. When
overexpressed in mice, APRIL induces B-cell neoplasia, reminiscent of human B-cell …
overexpressed in mice, APRIL induces B-cell neoplasia, reminiscent of human B-cell …
The future of CD20 monoclonal antibody therapy in B-cell malignancies
MS Czuczman, SA Gregory - Leukemia & lymphoma, 2010 - Taylor & Francis
Limitations of therapeutic options for chronic lymphocytic leukemia (CLL) and non-Hodgkin
lymphoma (NHL) have necessitated the development of novel treatments/strategies …
lymphoma (NHL) have necessitated the development of novel treatments/strategies …
Diagnosis and treatment of diffuse large B-cell lymphoma
U Mey, F Hitz, A Lohri, S Pederiva, C Taverna… - Swiss medical …, 2012 - zora.uzh.ch
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant
lymphoma in the Western world. It has an aggressive natural history, with a median survival …
lymphoma in the Western world. It has an aggressive natural history, with a median survival …
[HTML][HTML] Monoclonal antibody as therapy for malignant lymphomas
B Coiffier - Comptes rendus biologies, 2006 - Elsevier
Rituximab was the first monoclonal antibody to have been registered for the treatment of B-
cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma …
cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma …
[HTML][HTML] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
C Bodet-Milin, L Ferrer, A Pallardy, T Eugène… - Frontiers in …, 2013 - frontiersin.org
This manuscript reviews current advances in the use of radioimmunotherapy (RIT) for the
treatment of B-cell non-Hodgkin's lymphoma (NHL). RIT has been in use for more than 20 …
treatment of B-cell non-Hodgkin's lymphoma (NHL). RIT has been in use for more than 20 …
Current strategies for the treatment of diffuse large B cell lymphoma
B Coiffier - Current opinion in hematology, 2005 - journals.lww.com
Current strategies for the treatment of diffuse large B cell... : Current Opinion in Hematology
Current strategies for the treatment of diffuse large B cell lymphoma : Current Opinion in …
Current strategies for the treatment of diffuse large B cell lymphoma : Current Opinion in …
Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol
The addition of rituximab to conventional chemotherapy has significantly improved the
treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment …
treatment outcome in diffuse large B-cell lymphoma. However, differences in treatment …
The value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas
T Schrepfer, SK Haerle, K Strobel… - The …, 2010 - Wiley Online Library
Abstract Objectives/Hypothesis: Using a retrospective approach, the aim of this study was to
confirm the previously described value of fluorine‐18‐fluorodeoxyglucose positron emission …
confirm the previously described value of fluorine‐18‐fluorodeoxyglucose positron emission …